Helix BioPharma (TSE:HBP) has released an update.
Helix BioPharma Corp., a clinical-stage biopharmaceutical company, showcased its innovative L-DOS47 platform at the World ADC San Diego, highlighting its potential in treating hard-to-treat cancers. The company is advancing towards a Phase II study for non-small cell lung cancer and exploring broader applications across various cancer types. Helix aims to expand its pipeline with new antibody-drug conjugates, emphasizing the transformative potential of its technology in oncology.
For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.
